Patents by Inventor Hiroo Maeda
Hiroo Maeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141464Abstract: A steel sheet may be used for hot-dip galvanizing capable of manufacturing hot-dip galvannealed steel sheet(s) with a high Si content and in which alloying unevenness is suppressed. Such a steel sheet for hot-dip galvanizing may include an internal oxide layer containing an oxide of Si between a surface layer of the steel sheet and a steel sheet base portion. The Si content in a chemical composition of the steel sheet may be 1.0 mass % or more. A solid solution Si amount from a surface of the steel sheet to a depth of 1 ?m measured at all four positions including positions of 10 mm, 30 mm, and 50 mm from an edge in a coil width direction and a position of a center in the coil width direction at a rear end in a rolling direction of the steel sheet for hot-dip galvanizing may be 1.4 wt. % or less.Type: ApplicationFiled: March 2, 2022Publication date: May 2, 2024Applicant: Kabushiki Kaisha Kobe Seiko Sho (Kobe Steel, Ltd.)Inventors: Akira KAWAKAMI, Hiroo SHIGE, Hiroshi IRIE, Takayuki MAEDA, Hang YU
-
Publication number: 20240133013Abstract: A method for manufacturing a hot-dip galvanized steel sheet having a high Si content and good plating adhesion. The method for manufacturing a hot-dip galvanized steel sheet includes the following: hot-rolling a steel raw material having a Si content of 1.0 mass % or more and coiling a steel sheet at 500° C. to 700° C.; subjecting a surface of the steel sheet after the coiling to an oxidation treatment at a heating temperature of a steel sheet temperature of 750° C. or lower, and subsequently subjecting the surface to a reduction treatment; and subjecting the steel sheet after the reduction treatment to a hot-dip galvanizing treatment to form a Zn-plated layer on a surface of the steel sheet.Type: ApplicationFiled: March 2, 2022Publication date: April 25, 2024Applicant: KABUSHIKI KAISHA KOBE SEIKO SHO (Kobe Steel, Ltd.)Inventors: Akira KAWAKAMI, Hiroo SHIGE, Hiroshi IRIE, Takayuki MAEDA, Hang YU
-
Publication number: 20220062421Abstract: The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R1—O—R2 (1), wherein R1 is a hydrocarbon group having 8-24 carbon atoms, and R2 is a group represented by the formula (2): or a group represented by the formula (3): —(CH2CH2O)mH (3), wherein m is an integer of 1-18.Type: ApplicationFiled: November 17, 2021Publication date: March 3, 2022Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Masayasu TANAKA, Kazumitsu YAMAMOTO, Hiroo MAEDA, Koichi SAITO, Natsuko SUGINOBE
-
Publication number: 20150150975Abstract: The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R1—O—R2 (1), wherein R1 is a hydrocarbon group having 8-24 carbon atoms, and R2 is a group represented by the formula (2): or a group represented by the formula (3): —(CH2CH2O)mH (3), wherein m is an integer of 1-18.Type: ApplicationFiled: July 2, 2013Publication date: June 4, 2015Inventors: Masayasu Tanaka, Kazumitsu Yamamoto, Hiroo Maeda, Koichi Saito, Natsuko Suginobe
-
Publication number: 20140023695Abstract: A patch preparation containing a support and an adhesive layer formed on one surface of the support, wherein the adhesive layer contains 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine or a physiologically acceptable acid addition salt thereof, an acrylic polymer, lactic acid, sesame oil and one or more kinds of stabilizers selected from 2-mercaptobenzimidazole, 2,6-di-tert-butyl-4-methylphenol and propyl gallate. A patch preparation containing a support and an adhesive layer containing lactic acid and magnesium aluminometasilicate and formed on at least one surface of the support, which preparation is superior in both skin permeability and adhesiveness in the presence of water.Type: ApplicationFiled: February 1, 2012Publication date: January 23, 2014Inventors: Yasuaki Okada, Katsuhiro OKada, Masato Nishimura, Yuji Kawaharada, Hiroo Maeda, Kazumitsu Yamamoto, Masayasu Tanaka
-
Publication number: 20130315977Abstract: The present invention relates to an external preparation for transdermal administration, which remarkably enhances the skin permeability of 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (compound A). The adhesive preparation of the present invention has an adhesive layer formed on one surface of a support, and the adhesive layer contains (i) compound A or a physiologically acceptable acid addition salt thereof, (ii) an adhesive, (iii) lactic acid, and (iv) an additive containing a particular permeation enhancer, whereby remarkably superior skin permeability is provided.Type: ApplicationFiled: February 1, 2012Publication date: November 28, 2013Inventors: Hiroo Maeda, Kazumitsu Yamamoto, Masayasu Tanaka
-
Patent number: 8404803Abstract: First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFN?. Next, using analogue peptides of the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPGPLLVPFTLNFTITN (SEQ ID NO:11) is suitable for T cell activation.Type: GrantFiled: March 31, 2006Date of Patent: March 26, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Mitsuo Okubo, Hiroo Maeda, Satoru Takeda
-
Patent number: 8354121Abstract: It is intended to provide a preparation for percutaneous administration of 2-(4-ethyl-1-piperazinyl)-4-(4-fluoro-phenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (Compound A), which inhibits the generation of a metabolite and is capable of continuously maintaining a blood drug level. Specifically, a tape preparation comprising an adhesive layer formed on one surface of a support, characterized in that the adhesive layer contains (1) Compound A or a physiologically acceptable acid addition salt thereof, and (2) an acrylic adhesive, or (1) Compound A or a physiologically acceptable acid addition salt thereof, (2) an acrylic adhesive, and (3) a permeation enhancer is provided.Type: GrantFiled: June 7, 2007Date of Patent: January 15, 2013Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Hiroo Maeda, Naoki Ohara
-
Publication number: 20110229481Abstract: First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFN?. Next, using analogue peptides of the core protein MUC16 of the ovarian cancer-associated antibody C125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC16 of the ovarian cancer-associated antigen CA125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPOPLLVPFTLNFTITN (SEQ ID NO: 11) is suitable for T cell activation.Type: ApplicationFiled: March 31, 2006Publication date: September 22, 2011Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Mitsuo Okubo, Hiroo Maeda, Satoru Takeda
-
Patent number: 7601363Abstract: The present invention relates to a formulation for implantation having a novel constitution, which accomplishes controlled releases of active ingredients. The formulation comprises one of combinations (a), (b) and (c), as well as a carrier comprising a hydrophobic polymer, wherein the particle combination is dispersed into the carrier: (a) particles comprising an active ingredient, particles comprising a carbonate, and particles comprising a substance which is reacted with the carbonate in an aqueous solution to generate carbon dioxide (substance such as an acid); (b) particles comprising an active ingredient and a carbonate, and particles comprising a substance such as an acid; and (c) particles comprising a carbonate, and particles comprising an active ingredient and a substance such as an acid.Type: GrantFiled: March 19, 2007Date of Patent: October 13, 2009Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Akihiko Sano, Masako Kajihara, Hiroo Maeda
-
Publication number: 20090169605Abstract: It is intended to provide a preparation for percutaneous administration of 2-(4-ethyl-1-piperazinyl)-4-(4-fluoro-phenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (Compound A), which inhibits the generation of a metabolite and is capable of continuously maintaining a blood drug level. Specifically, a tape preparation comprising an adhesive layer formed on one surface of a support, characterized in that the adhesive layer contains (1) Compound A or a physiologically acceptable acid addition salt thereof, and (2) an acrylic adhesive, or (1) Compound A or a physiologically acceptable acid addition salt thereof, (2) an acrylic adhesive, and (3) a permeation enhancer is provided.Type: ApplicationFiled: June 7, 2007Publication date: July 2, 2009Inventors: Hiroo Maeda, Naoki Ohara
-
Publication number: 20070254887Abstract: A pharmaceutical composition for transdermal administration comprising perospirone of the formula (1): or a pharmaceutically acceptable acid addition salt thereof, which can inhibit the generation of metabolites and continuously maintain the blood level of perospirone.Type: ApplicationFiled: September 2, 2005Publication date: November 1, 2007Inventors: Hiroo Maeda, Naoki Ohara, Yuki Ikeda
-
Patent number: 7247312Abstract: The present invention relates to a formulation for implantation having a novel constitution, which accomplishes controlled releases of active ingredients. The formulation comprises one of combinations (a), (b) and (c), as well as a carrier comprising a hydrophobic polymer, wherein the particle combination is dispersed into the carrier: (a) particles comprising an active ingredient, particles comprising a carbonate, and particles comprising a substance which is reacted with the carbonate in an aqueous solution to generate carbon dioxide (substance such as an acid); (b) particles comprising an active ingredient and a carbonate, and particles comprising a substance such as an acid; and (c) particles comprising a carbonate, and particles comprising an active ingredient and a substance such as an acid.Type: GrantFiled: October 31, 2000Date of Patent: July 24, 2007Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Akihiko Sano, Masako Kajihara, Hiroo Maeda
-
Publication number: 20070166377Abstract: The present invention relates to a formulation for implantation having a novel constitution, which accomplishes controlled releases of active ingredients. The formulation comprises one of combinations (a), (b) and (c), as well as a carrier comprising a hydrophobic polymer, wherein the particle combination is dispersed into the carrier: (a) particles comprising an active ingredient, particles comprising a carbonate, and particles comprising a substance which is reacted with the carbonate in an aqueous solution to generate carbon dioxide (substance such as an acid); (b) particles comprising an active ingredient and a carbonate, and particles comprising a substance such as an acid; and (c) particles comprising a carbonate, and particles comprising an active ingredient and a substance such as an acid.Type: ApplicationFiled: March 19, 2007Publication date: July 19, 2007Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Akihiko Sano, Masako Kajihara, Hiroo Maeda
-
Patent number: 6887477Abstract: Preparations to be administered for treating or preventing ischemic diseases or arterial diseases which contain Hepatocyte growth factor (HGF) as an active ingredient. The preparations provide such effect that HGF concentration in an affected region to which HGF was administered is maintained, a half-life is longer, a dose can be reduced, and other organs except the affected region are less affected in comparison with intravenous administration.Type: GrantFiled: August 4, 1999Date of Patent: May 3, 2005Inventors: Tomokazu Nagano, Ikue Kudo, Takao Kawamura, Mutsuo Taiji, Hiroshi Noguchi, Shunsuke Tani, Hiroo Maeda
-
Publication number: 20040151723Abstract: An object of the present invention is to provide an epitope on a human papillomavirus antigen, which activates a CD4-positive T cell of a uterine cancer patient, and a CD4-positive T cell specific to cancerous and precancerous lesions of the uterus, which is activated by this epitope. An epitope according to the present invention comprises (a) the amino acid sequence of SEQ ID NO: 1, or (b) a modified amino acid sequence of the amino acid sequence of SEQ ID NO: 1 that has one or more modifications selected from the group consisting of a substitution, a deletion, an addition and an insertion and can activate CD4-positive T cells specific to cancerous and precancerous lesions of the uterus.Type: ApplicationFiled: December 4, 2003Publication date: August 5, 2004Inventors: Hiroo Maeda, Mitsuo Okubo
-
Patent number: 6756048Abstract: The present invention relates to a sustained release preparation of a lipophilic drug, comprising a drug dispersion wherein the lipophilic drug and a water-soluble substance are dispersed, in a solid state at the body temperature of an animal or a human being to which the preparation is to be administered, in a water-impermeable and biocompatible material.Type: GrantFiled: April 18, 2001Date of Patent: June 29, 2004Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Akihiko Sano, Hiroo Maeda, Masako Kajihara, Shunsuke Tani, Toshihiko Sugie
-
Patent number: 6143364Abstract: A batchwise hot dip plating method is performed by dipping a metallic material in a molten metal plating bath, following fluxing by dipping the metallic material in a bath of a fused salt flux (e.g., a mixture of cryolite and one or more alkali metal chlorides and optionally aluminum fluoride) having a melting temperature at least 5.degree. C. higher than the temperature of the molten metal plating bath, which also serves to preheat the metallic material. In the case of hot dip plating with an Al--Zn alloy, particularly a Zn/55% Al/0.5-2% Si alloy, a bare spot-free plated coating having good appearance can be formed by a reduced duration of dipping in the plating bath without post-plating treatment to remove flux residues. The use of a plating tank having a cross section of a round shape such as a semicircular shape or an oblong semielliptic shape, rather than a rectangular box shape, brings about a significantly extended service life of the plating tank.Type: GrantFiled: July 10, 1998Date of Patent: November 7, 2000Assignee: Sumitomo Metal Industries, Ltd.Inventors: Toshio Nakamori, Masashi Yamamoto, Tamotsu Toki, Hirohito Masumoto, Mutsuo Sagara, Hiroo Maeda
-
Patent number: 5342940Abstract: High purity polyethylene glycol derivatives of formula (I) are useful as protein modifiers of interferons, t-PA, EGF, various hormones, etc. The thus modified protein has minimized antigenicity, prolonged plasma half life, or improved transfer to tissue. A novel process for preparing high purity polyethylene glycol derivatives is also disclosed.Type: GrantFiled: September 13, 1993Date of Patent: August 30, 1994Assignees: Sumitomo Pharmaceuticals Company, Limited, Seikagaku CorporationInventors: Keiichi Ono, Yoshiyuki Kai, Hiroo Maeda
-
Patent number: 5214131Abstract: A polyethylene glycol derivative of the formula ##STR1## wherein R represents a lower alkyl and n represents an optional positive integer which renders the average molecular weight of the polyethylene glycol moiety about 1,000 to 12,000, a peptide modified by said polyethylene glycol derivative and a method for production thereof. The polyethylene glycol derivative (I) is capable of modifying the guanidino groups in peptides. The peptides modified by the polyethylene glycol derivative (I) are extremely stable, are considerably delayed in biological clearance (i.e. the durability is extended) and exhibit their physiological activities effectively over the long period.Type: GrantFiled: November 26, 1991Date of Patent: May 25, 1993Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Akihiko Sano, Hiroo Maeda, Yoshiyuki Kai, Keiichi Ono